上海凯宝(300039) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥400,639,141.82, a decrease of 15.74% compared to ¥475,496,607.80 in the same period last year[5] - Net profit attributable to shareholders was ¥84,292,812.22, down 4.71% from ¥88,458,934.18 year-on-year[5] - Total operating revenue decreased to ¥400,639,141.82 from ¥475,496,607.80, representing a decline of approximately 16%[19] - Net profit for the period was ¥84,140,700.39, down from ¥88,299,147.79, reflecting a decrease of around 4%[20] - Earnings per share (EPS) decreased to ¥0.0806 from ¥0.0846, a decline of approximately 3%[21] - Comprehensive income for the period was ¥106,398,595.34, compared to a loss of ¥253,160,871.64 in the previous period[21] Cash Flow - The net cash flow from operating activities increased by 21.70% to ¥88,768,706.33, compared to ¥72,941,777.87 in the previous year[5] - Cash inflow from operating activities was ¥388,104,420.35, down from ¥499,971,205.44, a decrease of about 22%[23] - Cash outflow from operating activities was ¥299,335,714.02, reduced from ¥427,029,427.57, a decline of approximately 30%[23] - The net cash flow from investment activities was $4,843,184.44, down from$29,808,363.98[24] - The cash flow from financing activities resulted in a net outflow of $22,051.25[24] - The net increase in cash and cash equivalents was$93,589,839.52, compared to $102,750,141.85 previously[24] - The ending balance of cash and cash equivalents was$675,640,218.25, up from $538,504,327.47[24] - The company received$799,848,507.06 from cash recovered from investments, an increase from $556,092,014.65[24] - The cash paid for the acquisition of fixed assets was$5,486,435.85, compared to $957,971.38 previously[24] - The company received$123,200,000.00 related to other investment activities, significantly up from $20,000.00[24] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,680,696,211.85, reflecting a 3.59% increase from ¥4,518,469,414.47 at the end of the previous year[5] - Non-current assets totaled ¥1,969,540,722.55, down from ¥2,103,100,033.03, indicating a decrease of about 6.35%[16] - Current liabilities increased to ¥284,738,696.31 from ¥232,302,504.59, representing a growth of about 22.58%[16] - Total liabilities rose to ¥471,277,326.41 from ¥415,449,124.37, an increase of approximately 13%[17] - Total equity attributable to shareholders increased to ¥4,208,602,270.52 from ¥4,102,051,563.35, reflecting a growth of about 2.6%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 54,640, with no preferred shareholders[11] - The top three shareholders held a combined 38.93% of the company's shares, with the largest shareholder owning 16.06%[11] Operational Highlights - The company reported a significant increase in investment income by 270.64%, primarily due to higher secondary market investment returns[9] - The company experienced a 40.90% decrease in other income, mainly due to reduced government subsidies related to daily operations[9] - The company reported a significant increase in accounts payable, which rose to ¥202,215,152.47 from ¥99,367,095.52, reflecting a growth of approximately 103.57%[16] - The company achieved a total current asset balance of ¥2,711,155,489.30, an increase from ¥2,415,369,381.44 at the beginning of the period, reflecting a growth of approximately 12.25%[15] - Cash and cash equivalents rose to ¥686,182,289.67 from ¥593,312,604.18, marking an increase of about 15.69%[15] - Accounts receivable increased to ¥321,166,688.92 from ¥316,503,090.30, showing a slight growth of approximately 1.05%[15] - The company’s inventory stood at ¥186,014,355.78, slightly down from ¥187,854,951.68, indicating a decrease of about 0.98%[15] - The company received drug registration certificates for traditional Chinese medicine products, enhancing its product line and market competitiveness[13] - The company’s subsidiary obtained registration for a new product, further diversifying its offerings[13] Other Financial Metrics - The weighted average return on equity improved to 2.56%, up 9.04% from -6.48% in the same period last year[5] - Deferred income increased slightly to ¥47,497,233.35 from ¥48,033,086.84, a decrease of about 1%[17] - The company reported a 332.27% increase in other current liabilities, attributed to the reclassification of certain bank acceptance bills[9] - Total operating costs decreased to ¥299,418,811.75 from ¥375,456,108.67, a reduction of about 20%[19] Audit Information - The first quarter report was not audited[25]